FIG 7.

Th17/IL-17A mediated B cell/antibody-independent protection in BALB/c mice, whereas Th1/IFN-γ inhibited protection in C57BL/6 mice. (A) BALB/c B cell-deficient mice treated with IL-17A neutralizing antibody prior to secondary SSTI had larger lesions than mice treated with an isotype control antibody (IgG) (n = 9 to 12 mice/group). (B) Treatment with IL-17A neutralizing antibody after immune T cell transfer resulted in larger lesions than were seen with mice that received an isotype control antibody (n = 8 mice/group). (C) C57BL/6 mice treated with IFN-γ neutralizing antibody prior to secondary SSTI had smaller lesions than mice treated with an isotype control antibody (IgG) (n = 6 to 8 mice/group). Data are presented as means ± SEM. *, P < 0.05 by Student's t test. The results of one representative experiment are presented; each was repeated at least once.